Traders Purchase Large Volume of Halozyme Therapeutics Call Options (HALO)
Shares of Halozyme Therapeutics (NASDAQ:HALO) was the target of unusually large options trading on Friday. Stock traders bought 7,934 call options on the stock, American Banking & Market News reports. This is an increase of approximately 411% compared to the average daily volume of 1,554 call options.
In other Halozyme Therapeutics news, Director John Stuart Patton sold 75,000 shares of the stock on the open market in a transaction dated Monday, September 16th. The stock was sold at an average price of $9.13, for a total value of $684,750.00. Following the completion of the sale, the director now directly owns 155,000 shares in the company, valued at approximately $1,415,150. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on HALO shares. Analysts at Jefferies Group cut their price target on shares of Halozyme Therapeutics (NASDAQ:HALO) from $4.50 to $4.00 in a research note to investors on Friday, August 2nd. They now have an “underperform” rating on the stock. Separately, analysts at Barclays Capital downgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from an “overweight” rating to an “equal weight” rating in a research note to investors on Friday, August 2nd. They now have a $8.00 price target on the stock, down previously from $9.00. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $7.93.
Shares of Halozyme Therapeutics (NASDAQ:HALO) traded up 6.91% on Friday, hitting $11.30. 6,327,400 shares of the company’s stock traded hands. Halozyme Therapeutics has a 52 week low of $4.80 and a 52 week high of $10.62. The stock’s 50-day moving average is $8.39 and its 200-day moving average is $7.1. The company’s market cap is $1.271 billion.
Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.13). The company had revenue of $14.50 million for the quarter, compared to the consensus estimate of $11.29 million. During the same quarter last year, the company posted ($0.13) earnings per share. Halozyme Therapeutics’s revenue was up 91.9% compared to the same quarter last year. Analysts expect that Halozyme Therapeutics will post $-0.68 EPS for the current fiscal year.
Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.